

Subject index¹

Volume 53 (2002)

Abacavir; FIV; In vitro; Antiretroviral; Zidovudine; Lamivudine; Hydroxyurea **53**, 35

Acridone; Antiviral; Viral assembly **53**, 113

Adenovirus; Milk proteins; Lactoferrin; Antiviral agents **53**, 153

2-aminopurine; Classical swine fever virus; LPS; Monocytes/macrophages; PKR (double-stranded RNA-dependent protein kinase); IFN; Poly(I)·poly(C); Antiviral effect **53**, 75

Antibody response; Hepatitis A vaccine; Hepatitis B vaccine; Combination vaccine **53**, 63

Anti-HIV-1 assay; HIV-1 *env* cloning vector; HIV-1/MuLV pseudotypes **53**, 99

Anti-HIV; Chemokine receptors; Binding; Transactivation; Ex-vivo cultures **53**, 1

Antiretroviral; FIV; In vitro; Zidovudine; Lamivudine; Abacavir; Hydroxyurea **53**, 35

Antiviral; Acridone; Viral assembly **53**, 113

Antiviral agents; Adenovirus; Milk proteins; Lactoferrin **53**, 153

Antiviral effect; Classical swine fever virus; LPS; Monocytes/macrophages; PKR (double-stranded RNA-dependent protein kinase); 2-aminopurine; IFN; Poly(I)·poly(C) **53**, 75

Ara-C; HIV-1; Cellular resistance; AZT; Mononucleotide; Prodrug **53**, 143

AZT; HIV-1; Cellular resistance; Ara-C; Mononucleotide; Prodrug **53**, 143

BCX-1812; Drug resistance; Cross-resistance; Resistance monitoring; Oseltamivir; Zanamivir; RWJ-270201; Neuraminidase inhibitors **53**, 47

Binding; Anti-HIV; Chemokine receptors; Transactivation; Ex-vivo cultures **53**, 1

Cellular resistance; HIV-1; AZT; Ara-C; Mononucleotide; Prodrug **53**, 143

Chemokine receptors; Anti-HIV; Binding; Transactivation; Ex-vivo cultures **53**, 1

Classical swine fever virus; LPS; Monocytes/macrophages; PKR (double-stranded RNA-dependent protein kinase); 2-aminopurine; IFN; Poly(I)·poly(C); Antiviral effect **53**, 75

Combination vaccine; Hepatitis A vaccine; Hepatitis B vaccine; Antibody response **53**, 63

Compensatory mutations; Cytomegalovirus; Ganciclovir; Phosphorylation UL97; Recombinant vaccinia viruses **53**, 135

Cross-resistance; Drug resistance; Resistance monitoring; Oseltamivir; Zanamivir; RWJ-270201; BCX-1812; Neuraminidase inhibitors **53**, 47

Cytomegalovirus; Ganciclovir; Phosphorylation UL97; Recombinant vaccinia viruses; Compensatory mutations **53**, 135

Dominant-negative polypeptide; HSV; Viral DNA replication; Gene regulation; Tetracycline **53**, 127

Drug resistance; Cross-resistance; Resistance monitoring; Oseltamivir; Zanamivir; RWJ-270201; BCX-1812; Neuraminidase inhibitors **53**, 47

Enterovirus; Picornavirus; Therapy; Prophylaxis; Rhinovirus **53**, 83

¹ The above Subject index includes issues 53/1 and 53/2. There is no Subject index for 53/3.

Epigallocatechin gallate (EGCg); HIV; Reverse transcriptase; Viral protease **53**, 19

Ex-vivo cultures; Anti-HIV; Chemokine receptors; Binding; Transactivation **53**, 1

FIV; In vitro; Antiretroviral; Zidovudine; Lamivudine; Abacavir; Hydroxyurea **53**, 35

Ganciclovir; Cytomegalovirus; Phosphorylation UL97; Recombinant vaccinia viruses; Compensatory mutations **53**, 135

Gene regulation; HSV; Viral DNA replication; Dominant-negative polypeptide; Tetracycline **53**, 127

Hepatitis A vaccine; Hepatitis B vaccine; Combination vaccine; Antibody response **53**, 63

Hepatitis B vaccine; Hepatitis A vaccine; Combination vaccine; Antibody response **53**, 63

Hepatitis C virus; TT virus; Interferon **53**, 9

HIV-1; Cellular resistance; AZT; Ara-C; Mononucleotide; Prodrug **53**, 143

HIV-1 env cloning vector; HIV-1/MuLV pseudotypes; *Anti-HIV-1* assay **53**, 99

HIV-1/MuLV pseudotypes; HIV-1 *env* cloning vector; *Anti-HIV-1* assay **53**, 99

HIV; Reverse transcriptase; Epigallocatechin gallate (EGCg); Viral protease **53**, 19

HSV; Viral DNA replication; Dominant-negative polypeptide; Gene regulation; Tetracycline **53**, 127

Human hepatoblastoma cell line; Ring-expanded nucleoside analogs; In vitro HBV inhibition; Low toxicity in stationary and fast-growing cell systems **53**, 159

Hydroxyurea; FIV; In vitro; Antiretroviral; Zidovudine; Lamivudine; Abacavir **53**, 35

IFN; Classical swine fever virus; LPS; Monocytes/macrophages; PKR (double-stranded RNA-dependent protein kinase); 2-aminopurine; Poly(I)-poly(C); Antiviral effect **53**, 75

Interferon; TT virus; Hepatitis C virus **53**, 9

In vitro; FIV; Antiretroviral; Zidovudine; Lamivudine; Abacavir; Hydroxyurea **53**, 35

In vitro HBV inhibition; Ring-expanded nucleoside analogs; Human hepatoblastoma cell line; Low toxicity in stationary and fast-growing cell systems **53**, 159

Lactoferrin; Adenovirus; Milk proteins; Antiviral agents **53**, 153

Lamivudine; FIV; In vitro; Antiretroviral; Zidovudine; Abacavir; Hydroxyurea **53**, 35

Low toxicity in stationary and fast-growing cell systems; Ring-expanded nucleoside analogs; In vitro HBV inhibition; Human hepatoblastoma cell line **53**, 159

LPS; Classical swine fever virus; Monocytes/macrophages; PKR (double-stranded RNA-dependent protein kinase); 2-aminopurine; IFN; Poly(I)-poly(C); Antiviral effect **53**, 75

Milk proteins; Adenovirus; Lactoferrin; Antiviral agents **53**, 153

Monocytes/macrophages; Classical swine fever virus; LPS; PKR (double-stranded RNA-dependent protein kinase); 2-aminopurine; IFN; Poly(I)-poly(C); Antiviral effect **53**, 75

Mononucleotide; HIV-1; Cellular resistance; AZT; Ara-C; Prodrug **53**, 143

Neuraminidase inhibitors; Drug resistance; Cross-resistance; Resistance monitoring; Oseltamivir; Zanamivir; RWJ-270201; BCX-1812 **53**, 47

Oseltamivir; Drug resistance; Cross-resistance; Resistance monitoring; Zanamivir; RWJ-270201; BCX-1812; Neuraminidase inhibitors **53**, 47

Phosphorylation UL97; Cytomegalovirus; Ganciclovir; Recombinant vaccinia viruses; Compensatory mutations **53**, 135

Picornavirus; Therapy; Prophylaxis; Rhinovirus; Enterovirus **53**, 83

PKR (double-stranded RNA-dependent protein kinase); Classical swine fever virus; LPS; Monocytes/macrophages; 2-aminopurine; IFN; Poly(I)-poly(C); Antiviral effect **53**, 75

Poly(I)-poly(C); Classical swine fever virus; LPS; Monocytes/macrophages; PKR (double-stranded RNA-dependent protein kinase); 2-aminopurine; IFN; Antiviral effect **53**, 75

Prodrug; HIV-1; Cellular resistance; AZT; Ara-C; Mononucleotide **53**, 143

Prophylaxis; Picornavirus; Therapy; Rhinovirus; Enterovirus **53**, 83

Recombinant vaccinia viruses; Cytomegalovirus; Ganciclovir; Phosphorylation UL97; Compensatory mutations **53**, 135

Resistance monitoring; Drug resistance; Cross-resistance; Oseltamivir; Zanamivir; RWJ-270201; BCX-1812; Neuraminidase inhibitors **53**, 47

Reverse transcriptase; HIV; Epigallocatechin gallate (EGCg); Viral protease **53**, 19

Rhinovirus; Picornavirus; Therapy; Prophylaxis; Enterovirus **53**, 83

Ring-expanded nucleoside analogs; In vitro HBV inhibition; Human hepatoblastoma cell line; Low toxicity in stationary and fast-growing cell systems **53**, 159

RWJ-270201; Drug resistance; Cross-resistance; Resistance monitoring; Oseltamivir; Zanamivir; BCX-1812; Neuraminidase inhibitors **53**, 47

Tetracycline; HSV; Viral DNA replication; Dominant-negative polypeptide; Gene regulation **53**, 127

Therapy; Picornavirus; Prophylaxis; Rhinovirus; Enterovirus **53**, 83

Transactivation; Anti-HIV; Chemokine receptors; Binding; Ex-vivo cultures **53**, 1

TT virus; Hepatitis C virus; Interferon **53**, 9

Viral assembly; Acridone; Antiviral **53**, 113

Viral DNA replication; HSV; Dominant-negative polypeptide; Gene regulation; Tetracycline **53**, 127

Viral protease; HIV; Reverse transcriptase; Epigallocatechin gallate (EGCg) **53**, 19

Zanamivir; Drug resistance; Cross-resistance; Resistance monitoring; Oseltamivir; RWJ-270201; BCX-1812; Neuraminidase inhibitors **53**, 47

Zidovudine; FIV; In vitro; Antiretroviral; Lamivudine; Abacavir; Hydroxyurea **53**, 35